Peter Tontonoz Selected Research

Liver X Receptors

1/2018	Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA.
11/2016	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
9/2015	Liver X receptors at the intersection of lipid metabolism and atherogenesis.
1/2014	The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis.
7/2013	Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance.
6/2012	LXRα is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice.
10/2011	An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
3/2011	Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease.
3/2011	Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target.
8/2010	Liver x receptor signaling pathways and atherosclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Tontonoz Research Topics

Disease

38	Atherosclerosis 12/2020 - 02/2002
28	Inflammation (Inflammations) 11/2022 - 02/2003
20	Obesity 01/2022 - 02/2002
12	Insulin Resistance 01/2021 - 02/2002
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 02/2002
7	Metabolic Diseases (Metabolic Disease) 07/2013 - 02/2002
6	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 06/2007
5	Dyslipidemias (Dyslipidemia) 01/2018 - 01/2006
4	Type 2 Diabetes Mellitus (MODY) 01/2018 - 07/2008
4	Infections 11/2014 - 06/2008
3	Fibrosis (Cirrhosis) 12/2021 - 03/2011
3	Neoplasms (Cancer) 01/2018 - 10/2011
3	Body Weight (Weight, Body) 07/2017 - 01/2012
3	Hypertriglyceridemia 01/2017 - 05/2002
2	Nervous System Diseases (Neurological Disorders) 01/2020 - 11/2013
2	Glucose Intolerance 01/2019 - 04/2016
2	Atherosclerotic Plaque (Atheroma) 01/2019 - 08/2010
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 07/2013
2	Hypertrophy 01/2018 - 09/2014
2	Neuroinflammatory Diseases 11/2015 - 06/2007
2	Virus Diseases (Viral Diseases) 11/2014 - 11/2006
2	Fatty Liver 01/2012 - 12/2002
2	Weight Gain 01/2012 - 05/2007
2	Hypercholesterolemia 08/2011 - 08/2007
2	Hyperlipidemias (Hyperlipidemia) 01/2005 - 01/2005
1	Cerebellar Ataxia (Dysmetria) 01/2020
1	Alcoholic Fatty Liver 01/2020
1	Hearing Loss (Hearing Impairment) 01/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2020
1	Polyneuropathies (Polyneuropathy) 01/2020
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/2020
1	Cataract (Cataracts) 01/2020
1	Carcinogenesis 01/2018
1	Kidney Diseases (Kidney Disease) 01/2018
1	Vascular Diseases (Vascular Disease) 01/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 12/2016
1	Brain Neoplasms (Brain Tumor) 11/2016
1	Glioblastoma (Glioblastoma Multiforme) 11/2016

Drug/Important Bio-Agent (IBA)

23	LipidsIBA 01/2022 - 09/2002
21	CholesterolIBA 12/2020 - 09/2002
21	Liver X ReceptorsIBA 01/2018 - 09/2002
13	LigandsIBA 12/2021 - 02/2002
10	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 04/2003
10	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2018 - 01/2004
8	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2009 - 05/2002
7	Apolipoproteins E (ApoE)IBA 01/2020 - 10/2006
5	Insulin (Novolin)FDA Link 01/2021 - 12/2009
5	LDL Receptors (LDL Receptor)IBA 01/2018 - 10/2011
4	Transcription Factors (Transcription Factor)IBA 11/2022 - 10/2006
4	Estrogen ReceptorsIBA 01/2020 - 02/2015
4	SterolsIBA 01/2018 - 07/2008
4	Triglycerides (Triacylglycerol)IBA 01/2017 - 11/2011
4	oxidized low density lipoproteinIBA 08/2011 - 03/2005
4	PPAR gammaIBA 01/2008 - 02/2002
3	CytokinesIBA 11/2018 - 08/2005
3	Biological ProductsIBA 01/2018 - 07/2015
3	Long Noncoding RNAIBA 01/2018 - 01/2017
3	Phospholipids (Phosphatides)FDA LinkGeneric 01/2018 - 11/2013
3	Sterol Regulatory Element Binding Protein 1IBA 10/2017 - 10/2011
3	Lipoproteins (Lipoprotein)IBA 01/2017 - 06/2008
3	ApolipoproteinsIBA 11/2015 - 06/2008
3	GW 3965IBA 10/2011 - 04/2003
2	Amyloid (Amyloid Fibrils)IBA 01/2020 - 11/2015
2	LDL CholesterolIBA 01/2018 - 08/2011
2	AutoantibodiesIBA 01/2017 - 08/2009
2	Pharmaceutical PreparationsIBA 11/2016 - 08/2007
2	Phosphotransferases (Kinase)IBA 11/2016 - 11/2013
2	Antiviral Agents (Antivirals)IBA 11/2014 - 11/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 03/2004
2	Proteins (Proteins, Gene)FDA Link 09/2010 - 01/2005
2	Fatty Acids (Saturated Fatty Acids)IBA 06/2009 - 10/2008
2	Interleukin-6 (Interleukin 6)IBA 11/2008 - 02/2003
2	AdipokinesIBA 01/2008 - 01/2007
1	Interferon Regulatory FactorsIBA 11/2022
1	ChemokinesIBA 12/2021
1	CollagenIBA 12/2021
1	Sucrose (Saccharose)IBA 12/2021
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2021
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2021
1	LysophospholipidsIBA 01/2021
1	PhosphatidylserinesIBA 01/2020
1	Lipoprotein Receptors (Lipoprotein Receptor)IBA 01/2020
1	Lipase (Acid Lipase)FDA Link 01/2020
1	Mitochondrial DNA (mtDNA)IBA 01/2020
1	AntioxidantsIBA 01/2019
1	Interleukin-10 (Interleukin 10)IBA 11/2018
1	Interleukin-10 ReceptorsIBA 11/2018
1	LeptinIBA 01/2018
1	Brachyury protein (Brachyury)IBA 01/2018
1	enhanced green fluorescent proteinIBA 01/2018
1	polyene phosphatidylcholineIBA 10/2017
1	phenylamilIBA 07/2017
1	Ezetimibe (Zetia)FDA Link 01/2017
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2016
1	Growth Factor ReceptorsIBA 11/2016
1	2- (2- chloro- 4- fluorobenzyl)- 3- (4- fluorophenyl)- 7- (trifluoromethyl)- 2H- indazoleIBA 11/2016

Therapy/Procedure

1	Oral Administration 07/2017